CFDA Wants To Speed Up Timeframe For E-Monitoring Of Sterile Drugs
This article was originally published in PharmAsia News
China FDA wants to speed-up the timeframe for electronic monitoring implementation for sterile drugs by a year to the end of 2013.
You may also be interested in...
AdvaMed Accell executive director Ashley Wittorf spoke in support of a proposed US House bill that would give financial help to small companies making products to address COVID-19.
Risdiplam’s efficacy across two clinical trials and oral dosing made it a credible threat before its US FDA approval, but its weight-based pricing falls below Biogen’s Spinraza and Novartis’s Zolgensma.
A pilot that used RFID tags with 2D barcodes was touted as more effective than using 2D barcodes alone in tracking drugs through the supply chain.